In Brief
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.
You may also be interested in...
MidNite PM “Sleep Fast” And Pain Relief Claims Unsubstantiated – NAD
Meda Consumer Healthcare appeals a NAD decision to the National Advertising Review Board. Meda’s evidence failed to show whether its proprietary blend or the individual ingredients provide MidNite PM’s benefits, NAD says, and stating that each ingredient has “calming properties” is “insufficient to support the claim.”
MidNite PM “Sleep Fast” And Pain Relief Claims Unsubstantiated – NAD
Meda Consumer Healthcare appeals a NAD decision to the National Advertising Review Board. Meda’s evidence failed to show whether its proprietary blend or the individual ingredients provide MidNite PM’s benefits, NAD says, and stating that each ingredient has “calming properties” is “insufficient to support the claim.”
In Brief
Zeller heads FDA tobacco center; FDA denies P&G diabetes claim; Meda depends on OTCs; Ocean Nutrition boosts DSM; Elcelyx innovates in financing round; FDA warns DMAA firm on GMP violations; probiotics get Canadian claim approval.